Search global stocks & ETFs...Ctrl K

Learn Mode

REGN - Regeneron Pharmaceuticals Inc

151

$698.25

-$14.62 (-2.051%)

At market close

$697.16

-$1.10 (-0.157%)

After Hours 5/15/26, 10:53 PM

Score

3.80/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

REGN

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$73.20B

Industry

Biotechnology

EPS (TTM)

$41.07

P/E (TTM)

16.55

Div & Yield

$3.76 (0.54%)

FCF Payout Ratio

10.40%

P/S (TTM)

4.91

P/B

2.33

Diluted Shares

107.70M

Ex-Dividend

2026-05-20

Next Earnings

07-30

Forward P/E

13.92

Payout Ratio

8.91%

P/FCF (TTM)

19.31

FCF Yield

5.18%

Earnings Yield

6.04%

52 Week Range

Score Card

Explore Scores Tab

3.80

Good

Regeneron Pharmaceuticals Inc has grown revenue at 5.92% over the past year, which suggests sales are increasing. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

1.00

Very Bad

Growth

4.00

Good

Profitability

4.00

Good

Fin. Health

4.00

Good

Dividends

5.00

Very Good

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form 13F-HR

Unknown Form Type

Filed on 2026-05-08 16:09:13

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:14:55

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-30 13:03:31

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-04-29 06:54:54

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-29 06:50:22

Form ARS

Unknown Form Type

Filed on 2026-04-24 16:12:11

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-24 16:04:21

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-24 16:02:55

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-08 07:05:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-03 16:01:09

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 11:37:27

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 16:01:53

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$1,110

58.9%

Avg:

$885

26.7%

Low:

$667

-4.5%

(% change is relative to the current stock price: $698.25)

Analyst Recommendations

Go to Analyst Tab

4.08

Good

29%

Strong Buy (11)

50%

Buy (19)

21%

Hold (8)

Sell (0)

Strong Sell (0)

About

Website
https://www.regeneron.com/
Address
777 Old Saw Mill River Road, Tarrytown NEW YORK, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=872589

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

IPO Date

1991-04-02

Industry

Biotechnology

Total Employees

15,410

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

REGN - Regeneron Pharmaceuticals Inc

151

$698.25

-$14.62 (-2.051%)

$697.16

-$1.10 (-0.157%)

3.80/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form 13F-HR

Filed on 2026-05-08 16:09:13

Form 4

Filed on 2026-05-04 16:14:55

Form SCHEDULE 13G

Filed on 2026-04-30 13:03:31

Form 10-Q

Filed on 2026-04-29 06:54:54

Form 8-K

Filed on 2026-04-29 06:50:22

Form ARS

Filed on 2026-04-24 16:12:11

Form DEFA14A

Filed on 2026-04-24 16:04:21

Form DEF 14A

Filed on 2026-04-24 16:02:55

Form 8-K

Filed on 2026-04-08 07:05:58

Form 4

Filed on 2026-04-03 16:01:09

Form SCHEDULE 13G/A

Filed on 2026-03-27 11:37:27

Form 4

Filed on 2026-03-03 16:01:53

Financials

Price Targets

58.9%

26.7%

-4.5%

Analyst Recommendations

About

Similar Stocks